{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ISRG",
  "name": "Intuitive Surgical, Inc.",
  "url": "https://frontierpicks.com/dossiers/ISRG/",
  "json_url": "https://frontierpicks.com/dossiers/ISRG.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a1",
    "n": 1
  },
  "current_thesis": "Intuitive Surgical's revenue grew 19% last quarter while its shares trade 29.9% below their 52-week high; the 20 October 2026 third-quarter report shows whether procedure growth holds inside the 13.5%–15.5% full-year guidance.",
  "invalidation_trigger": "A daily close below $351, under the 2026-09-09 close of $351.13 that started the September rebound; or a cut to the 13.5%–15.5% 2026 procedure growth guidance at the 2026-10-20 report.",
  "catalyst_date": "2026-10-20",
  "pick": {
    "id": "P-2026-10-01-ISRG",
    "conviction": "MEDIUM",
    "status": "open",
    "opened": "2026-10-01",
    "open_close": 401.24,
    "kill_level": 351,
    "kill_basis": "daily",
    "horizon_end": "2026-12-31",
    "last_date": "2026-10-09",
    "last_close": 423.96,
    "return_pct": 5.66,
    "spy_return_pct": 1.91,
    "excess_pp": 3.75,
    "kill_distance_pct": 20.786324786324784,
    "closed": null,
    "close_reason": null,
    "outcome": null,
    "scoreboard": "https://frontierpicks.com/track-record/"
  },
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Intuitive Surgical pays no dividend; it returns capital through share repurchases, including 0.9 million shares for $0.38 billion in the second quarter of 2026.",
    "Intuitive reports procedure growth and system placements each quarter; these operating figures often move the shares more than earnings per share does.",
    "Intuitive reports quarterly results after the US market close, so the share reaction shows up in the following session.",
    "Intuitive faces continuing antitrust litigation over third-party remanufactured instruments, including Surgical Instrument Service Co. v. Intuitive Surgical in the Ninth Circuit."
  ],
  "body_markdown": "## Current Thesis\n\nIntuitive Surgical's business is still growing faster than its share price implies. Revenue rose 19% in the second quarter of 2026, yet the shares closed at $415.41 on 2026-10-08, 29.9% below their 52-week high of $592.85. The third-quarter report on 2026-10-20, after the market close, settles the case. It shows whether procedure growth holds inside the 13.5%–15.5% full-year range or slows enough to justify the lower price.\n\nTwo things changed since the 2026-10-07 note. The shares rose from $404.76 on 2026-10-06 to $415.41 on 2026-10-08. Barclays started coverage on 2026-10-07 with an Overweight rating and a $485 target, arguing that strong medtech names look attractive after the sector's weakness and that industry fundamentals should stabilise in 2027 (Benzinga; goldesel.de). The company's investor relations calendar confirms the earnings call for 2026-10-20 at 1:30 p.m. Pacific time.\n\nThe narrative is maturing: the da Vinci story is widely known, and the Barclays initiation on 2026-10-07 rests on a sector-recovery argument rather than new company results. Barchart measured the shares down 8.4% over the 52 weeks to 2026-09-30, while the S&P 500 gained 15.2%. Expectations going into the report already look reset lower, which is the core of the case.\n\n## Bull Case\n\n- **Revenue and earnings still compounding.** Second-quarter 2026 revenue was $2.89 billion, up 19% from $2.44 billion. Non-GAAP diluted EPS (earnings per share) was $2.80, against $2.19 a year earlier (company release, 2026-07-16).\n- **Procedures, the recurring driver, grew 16%.** Worldwide procedures grew about 16% in the second quarter, with da Vinci up about 15% and Ion up about 36% (company release, 2026-07-16). Instruments and accessories, bought for every procedure, brought in $1.73 billion, up 18%.\n- **New system cycle is adding placements.** The company placed 468 da Vinci systems in the quarter against 395 a year earlier, including 246 da Vinci 5 units against 180 (company release, 2026-07-16). The installed base reached 11,710 systems.\n- **Approved uses keep widening.** Da Vinci 5 won CE mark approval in Europe for adult cardiac procedures, including minimally invasive coronary bypass, on 2026-09-29 (MDDI). Da Vinci SP won expanded European gynecologic use earlier in September (ad-hoc-news, 2026-09-16).\n- **The valuation has already compressed.** GuruFocus put the price-to-earnings ratio at 46.6 times on 2026-10-05, against a five-year median of 70.9 times. Analysts expect 2026 EPS of $10.78, up 20.71% (stockanalysis.com, 2026-10-05).\n- **Analyst support is broadening.** Barclays initiated at Overweight with a $485 target on 2026-10-07 (Benzinga). RBC Capital set a $575 target with a Buy rating on 2026-10-01 (ad-hoc-news), and Barchart counted 22 \"Strong Buy\" ratings among 31 analysts on 2026-09-30.\n\n## Bear Case\n\n- **Guidance implies a slower second half.** Management guided 2026 procedure growth to 13.5%–15.5%, \"closer to the midpoint\" (company release, 2026-07-16). That range sits below the 17% of the first quarter and the 16% of the second.\n- **The US business is decelerating.** An Intuitive executive said on 2026-09-09 that the US business, about 60% of operations, is slowing (Benzinga). The company pointed to a planned 2027 extended-use instrument program as a later support for procedure growth, which places the help outside this report.\n- **Quarterly earnings growth is expected to slow.** Barchart's consensus of $2.13 per share for the third quarter implies 8.7% growth from $1.96 (2026-09-30), well below the 28% EPS growth of the second quarter.\n- **Tariffs weigh on margin.** The 2026 gross margin guide of 68.0%–69.0% already includes a tariff cost of about 1.0% of revenue (company release, 2026-07-16). A wider tariff hit would land directly on that range.\n- **Antitrust exposure has reopened.** Intuitive asked the full Ninth Circuit on 2026-09-29 to rehear a panel decision that revived antitrust claims over remanufactured instruments in Surgical Instrument Service Co. v. Intuitive Surgical (Law360).\n- **Earnings reactions have been sharp.** The shares fell 14.2% the session after the 2026-07-16 report (TipRanks). A soft US procedure number could repeat that move.\n\n## Setup & Price Structure\n\nThe shares closed at $415.41 on 2026-10-08, up from $406.48 on 2026-10-05 and $404.76 on 2026-10-06, in adjusted daily closes. They sit 29.9% below the 52-week high of $592.85 and are up 2.0% over three months. The September rebound began from a close of $351.13 on 2026-09-09.\n\nThe 14-day relative strength index (RSI), a momentum gauge, read 64.0 on 2026-10-08. That reflects firm buying into the report without reaching the 70 level usually read as overbought.\n\nCrowding evidence is moderate. The earnings date is eight trading sessions away, and Benzinga's 2026-09-30 pieces framing Intuitive as a \"physical AI\" leader drew retail attention to the name. The three-month gain of 2.0% and the 29.9% gap to the 52-week high show the shares are not extended against their recent history.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-10-20, after the market close: third-quarter 2026 report and call (1:30 p.m. Pacific).** The report shows whether worldwide procedure growth stays inside 13.5%–15.5%, how far US growth slows, whether da Vinci 5 placements keep rising from 246 in the second quarter, and whether tariffs force a cut to the 68.0%–69.0% gross margin guide. Some data aggregators list 2026-10-19; the company's investor relations event page lists 2026-10-20.\n- **Date not set: Ninth Circuit ruling on Intuitive's petition for full-court rehearing.** A denial would send the revived remanufactured-instrument claims back toward trial.\n\n## What Would Change Our Mind\n\nThe case breaks if the third-quarter report shows procedures slowing faster than guidance allows. Worldwide procedure growth near or below 13.5%, or a lowered 2026 procedure range on 2026-10-20, would show the share-price discount is justified. A cut to the 68.0%–69.0% gross margin guide, or instruments and accessories growth falling well behind procedure growth, would also weaken it.\n\nOn price, a daily close below $351, under the 2026-09-09 close of $351.13 that started the September rebound, would erase the whole recovery and end the thesis. A Ninth Circuit denial of rehearing would add a legal overhang without breaking the operating case on its own.\n\nThe case strengthens if procedure growth lands at or above the 14.5% guidance midpoint and US growth stabilises.\n\n## Correlation Notes\n\nIntuitive trades with large-cap medical technology. Barclays' 2026-10-07 initiation explicitly ties its view to a sector recovery, so a further medtech sell-off would pressure the shares even on solid results. The Medtech & diagnostics theme cluster has been heating since late September, but its peers (Illumina, Natera, Grail and other genomics names) are diagnostics businesses, and Intuitive's read depends on its own procedure numbers rather than on that group.\n\nThe \"physical AI\" framing in Benzinga's 2026-09-30 coverage links the shares to robotics funds such as BOTZ. That adds sensitivity to swings in the AI and robotics trade that the hospital business itself does not drive.",
  "first_seen": "2026-10-01",
  "last_analyzed": "2026-10-09T08:27:03+00:00",
  "last_synthesized": "2026-10-09",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}